Alpha Centric Advisors LLC Atreca, Inc. Transaction History

Alpha Centric Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	SELL	$2.87 - $6.29 $172,200 - $377,400	-60,000 Closed	0 $0
Q3 2021 Mar 09, 2022	SELL	$4.91 - $9.07 $31,915 - $58,955	-6,500 Reduced 9.77%	60,000 $374,000
Q2 2021 Mar 09, 2022	BUY	$7.82 - $13.8 $441,830 - $779,700	56,500 Added 565.0%	66,500 $567,000
Q1 2021 Mar 09, 2022	BUY	$13.0 - $19.34 $52,000 - $77,360	4,000 Added 66.67%	10,000 $153,000
Q4 2020 Mar 11, 2022	BUY	$13.03 - $17.09 $78,180 - $102,540	6,000 New	6,000 $97,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.